Table 4.
Outcomes in PwP participants whose PKG scores were out of target at first visit.
| 1st visit | Last visit | ||||
|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | P val | Δ SEM | 95% CI | |
| PKG + ARM (N = 54) | |||||
| UPDRSa Total | 62.8 ± 16.4 | 51.1 ± 15.5 | <0.001* | 11.6 ± 3.0 | 5.8–17.5 |
| UPDRS IV | 5.6 ± 3.8 | 3.3 ± 3.0 | <0.001* | 2.3 ± 0.6 | 1.1–3.6 |
| UPDRS III | 36.5 ± 9.4 | 28.6 ± 8.3 | <0.001* | 7.9 ± 1.7 | 4.6–11.2 |
| UPDRS II | 10.3 ± 5.9 | 9.5 ± 6.0 | 0.48 | 0.8 ± 1.1 | −1.4 to 3.0 |
| UPDRS I | 11.0 ± 4.6 | 10.1 ± 5.0 | 0.31 | 0.9 ± 0.9 | −0.8 to 2.7 |
| PDQ39b | 28.1 ± 17.4 | 22.1 ± 13.8 | 0.045* | 6.1 ± 2.9 | 0.3–11.8 |
| mBKSc | 26.4 ± 5.6 | 24.2 ± 3.7 | 0.016* | 2.2 ± 0.9 | 0.4–3.9 |
| AmBKSd | 23.6 ± 5.5 | 21.5 ± 3.8 | 0.023* | 2.1 ± 0.9 | 0.3–3.8 |
| PTOTe | 23.8 ± 18.0 | 14.3 ± 11.5 | 0.001* | 9.5 ± 2.8 | 4.0–15.1 |
| PTTf | 5.4 ± 9.9 | 3.0 ± 5.9 | 0.116 | 2.4 ± 1.5 | −0.6 to 5.4 |
| PTIg | 6.8 ± 5.6 | 5.9 ± 5.3 | 0.38 | 0.9 ± 1.0 | −1.1 to 2.9 |
| mDKSh | 3.0 ± 3.8 | 3.0 ± 2.4 | 0.98 | 0.0 ± 0.6 | −1.2 to 1.2 |
| PTDi | 10.5 ± 11.0 | 12.1 ± 8.7 | 0.39 | −1.6 ± 1.9 | −5.2 to 2.0 |
| LEDDj | 669 ± 299 | 823 ± 369 | 0.02* | −155 ± 63 | −278 to 32 |
| MoCAk | 26.3 ± 2.2 | 26.4 ± 2.3 | 0.83 | −0.1 ± 0.4 | −0.9 to 0.7 |
| NMSl | 8.9 ± 5.1 | 8.2 ± 5.3 | 0.49 | 0.7 ± 1.0 | −1.2 to 2.6 |
| SENS PDm | 11.7 ± 5.1 | 9.8 ± 4.6 | 0.17 | 1.8 ± 0.9 | 0.1–3.6 |
| PKG-ARM (N = 57) | |||||
| UPDRS Total | 67.4 ± 19.0 | 61.1 ± 18.4 | 0.09 | 6.2 ± 3.6 | −0.9 to 13.3 |
| UPDRS IV | 5.2 ± 3.6 | 4.0 ± 3.4 | 0.09 | 1.2 ± 0.7 | −0.1 to 2.5 |
| UPDRS III | 38.5 ± 10.9 | 34.8 ± 10.4 | 0.08 | 3.7 ± 2.0 | −0.3 to 7.7 |
| UPDRS II | 11.9 ± 6.6 | 11.1 ± 6.5 | 0.56 | 0.7 ± 1.3 | −1.7 to 3.2 |
| UPDRS I | 11.8 ± 6.2 | 11.2 ± 4.8 | 0.57 | 0.6 ± 1.1 | −1.5–2.7 |
| PDQ39 | 32.6 ± 20.6 | 29.5 ± 19.6 | 0.43 | 3.1 ± 3.9 | −4.5 to 10.7 |
| mBKS | 27.3 ± 5.9 | 25.7 ± 5.9 | 0.18 | 1.5 ± 1.1 | −0.7 to 3.8 |
| AmBKS | 24.6 ± 5.6 | 23.4 ± 5.7 | 0.28 | 1.2 ± 1.1 | −0.9–3.3 |
| PTOT | 27.9 ± 22.2 | 21.7 ± 19.1 | 0.13 | 6.2 ± 4.0 | −1.6 to 14.0 |
| PTT | 6.7 ± 8.9 | 4.8 ± 7.0 | 0.23 | 1.9 ± 1.5 | −1.1 to 4.9 |
| PTI | 6.8 ± 6.7 | 6.9 ± 6.3 | 0.91 | −0.1 ± 1.3 | −2.6 to 2.3 |
| mDKS | 2.8 ± 4.4 | 3.2 ± 3.7 | 0.55 | −0.5 ± 0.8 | −2.0 to 1.1 |
| PTD | 9.4 ± 12.1 | 12.8 ± 12.4 | 0.15 | −3.5 ± 2.4 | −8.1 to 1.1 |
| LEDD | 760 ± 357 | 933 ± 381 | 0.02 | −173 ± 71 | −312 to 33 |
| MoCA | 25.8 ± 2.5 | 26.4 ± 2.9 | 0.28 | −0.6 ± 0.5 | −1.6 to 0.4 |
| Base NMS | 10.2 ± 5.3 | 9.4 ± 4.9 | 0.45 | 0.7 ± 1.0 | −1.2 to 2.7 |
| SENS PD | 12.7 ± 5.3 | 12.4 ± 5.2 | 0.77 | 0.3 ± 1.0 | −1.7 to 2.3 |
Δ = difference. *P < 0.05.
aMovement Disorder Society Unified Parkinson’s Disease Rating Scale. bParkinson’s Disease Quality of Life 39 Questions. cMedian of 2 min Bradykinesia Scores. dMedian of 2 min active Bradykinesia Scores. ePercent time over target. fPercent time in tremor. gPercent time immobile (day time sleep surrogate): mDKS. hMedian of 2 min Dyskinesia Scores: PTD. iPercent time in dyskinesia. jLevodopa equivalent daily dose. kMontreal Cognitive Assessment. lNon-Motor Symptoms Questionnaire. mSeverity of predominantly Non-dopaminergic Symptoms in Parkinson’s Disease.